All In MedTech

FDA Clearance Tracker · P100018-S048

Pipeline™ Vantage Embolization Device with Shield Technology™

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Aug 14, 2025 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Aug 14, 2025

Approved

Time to decision

197 days

Received Jan 29, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P100018-S048
Device name
Pipeline™ Vantage Embolization Device with Shield Technology™
Applicant location
Irvine, CA
Received
Jan 29, 2025
Decided
Aug 14, 2025
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P100018

Device type

Device class
Class III

Every decision under product code OUT

FDA's approval statement

As written in FDA's record.

Approval for changes to the post-approval study (PAS) protocol for Pipeline Vantage device following the removal of the Vantage 027 devices, including updates to include additional follow-up imaging to assess for braid deformation events.

Source documents

Other decisions for Micro Therapeutics, Inc. d/b/a ev3 Neurovascular

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.